Clinical trial
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for…
NCT00181584 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00181584 |
|---|---|
| Title | Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer |
| Official title | Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bone Loss, Prostate Cancer |
| Intervention type | Drug, Other |
| Interventions | Zoledronic acid, Placebo |
| Enrollment | 60 |
| Start date | Sep 1, 2003 |
| Primary completion | Feb 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Jul 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: